Literature DB >> 27895033

Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.

Daniela F Quail1,2, Johanna A Joyce3,4.   

Abstract

Tumor-associated macrophages (TAMs) are a major cellular component of numerous tumor types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy. Here, we review preclinical and clinical strategies to target macrophages in cancer and discuss potential explanations for why some strategies are effective while other approaches have shown limited success. Clin Cancer Res; 23(4); 876-84. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27895033      PMCID： PMC5453188          DOI： 10.1158/1078-0432.CCR-16-0133

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  93 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Latent enhancers activated by stimulation in differentiated cells.

Authors:  Renato Ostuni; Viviana Piccolo; Iros Barozzi; Sara Polletti; Alberto Termanini; Silvia Bonifacio; Alessia Curina; Elena Prosperini; Serena Ghisletti; Gioacchino Natoli
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

4.  Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors:  Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-01       Impact factor: 3.333

Review 5.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

Authors:  Michele De Palma; Craig Murdoch; Mary Anna Venneri; Luigi Naldini; Claire E Lewis
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

Review 6.  The significance of cancer cell expression of the chemokine receptor CXCR4.

Authors:  Fran Balkwill
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

7.  Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

Authors:  Michael B Atkins; Gwenaelle Gravis; Kazimierz Drosik; Tomasz Demkow; Piotr Tomczak; Shirley S Wong; M Dror Michaelson; Toni K Choueiri; Benjamin Wu; Lynn Navale; Douglas Warner; Alain Ravaud
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 8.  CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

Authors:  Carola H Ries; Sabine Hoves; Michael A Cannarile; Dominik Rüttinger
Journal:  Curr Opin Pharmacol       Date:  2015-06-04       Impact factor: 5.547

9.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110
View more
  44 in total

Review 1.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

Review 2.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

Review 3.  The Tumor Microenvironment Innately Modulates Cancer Progression.

Authors:  Dominique C Hinshaw; Lalita A Shevde
Journal:  Cancer Res       Date:  2019-07-26       Impact factor: 12.701

4.  CSF-1R regulates non-small cell lung cancer cells dissemination through Wnt3a signaling.

Authors:  Yan Xia Yu; Hai Jian Wu; Bing Xu Tan; Chen Qiu; Hui Zhong Liu
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 5.  Tobacco and alcohol as risk factors for pancreatic cancer.

Authors:  Murray Korc; Christie Y Jeon; Mouad Edderkaoui; Stephen J Pandol; Maxim S Petrov
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-09-06       Impact factor: 3.043

6.  Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Authors:  Amaia Martinez-Usatorre; Ece Kadioglu; Gael Boivin; Chiara Cianciaruso; Alan Guichard; Bruno Torchia; Nadine Zangger; Sina Nassiri; Ioanna Keklikoglou; Martina Schmittnaegel; Carola H Ries; Etienne Meylan; Michele De Palma
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

7.  Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma.

Authors:  Xao X Tang; Hiroyuki Shimada; Naohiko Ikegaki
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

8.  Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.

Authors:  Quan Zhang; Junwen Wang; Xiaolong Yao; Sisi Wu; Weidong Tian; Chao Gan; Xueyan Wan; Chao You; Feng Hu; Suojun Zhang; Huaqiu Zhang; Kai Zhao; Kai Shu; Ting Lei
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

9.  Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.

Authors:  Sarah A O'Brien; Jessica Orf; Katarzyna M Skrzypczynska; Hong Tan; Jennie Kim; Jason DeVoss; Brian Belmontes; Jackson G Egen
Journal:  Cancer Immunol Immunother       Date:  2021-01-29       Impact factor: 6.968

10.  Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.

Authors:  David Gyori; Ee Lyn Lim; Francis M Grant; Dominik Spensberger; Rahul Roychoudhuri; Stephen J Shuttleworth; Klaus Okkenhaug; Len R Stephens; Phillip T Hawkins
Journal:  JCI Insight       Date:  2018-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.